Compare Stocks: MLTX, LEGN, TNGX, and TLX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LEGN Legend Biotech	$18.62 -0.5%	$19.81	$16.24 ▼ $37.50	$3.63B	0.57	2.42 million shs	1.39 million shs
MLTX MoonLake Immunotherapeutics	$10.82 +2.3%	$14.27	$8.80 ▼ $23.29	$900.43M	1.08	2.06 million shs	2.01 million shs
TLX Telix Pharmaceuticals	$11.21 +1.8%	$11.50	$6.28 ▼ $13.11	$3.74B	-0.17	517,723 shs	313,022 shs
TNGX Tango Therapeutics	$23.81 +5.5%	$24.43	$6.69 ▼ $34.39	$3.81B	1.17	3.45 million shs	3.10 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LEGN Legend Biotech	-0.48%	+0.27%	-6.48%	-31.24%	-42.19%
MLTX MoonLake Immunotherapeutics	+2.27%	-5.17%	-21.14%	-46.86%	+18.90%
TLX Telix Pharmaceuticals	+1.82%	+6.26%	-9.16%	+0.63%	+9.47%
TNGX Tango Therapeutics	+5.49%	+2.45%	-0.79%	-23.34%	+244.57%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LEGN Legend Biotech	$18.62 -0.5%	$19.81	$16.24 ▼ $37.50	$3.63B	0.57	2.42 million shs	1.39 million shs
MLTX MoonLake Immunotherapeutics	$10.82 +2.3%	$14.27	$8.80 ▼ $23.29	$900.43M	1.08	2.06 million shs	2.01 million shs
TLX Telix Pharmaceuticals	$11.21 +1.8%	$11.50	$6.28 ▼ $13.11	$3.74B	-0.17	517,723 shs	313,022 shs
TNGX Tango Therapeutics	$23.81 +5.5%	$24.43	$6.69 ▼ $34.39	$3.81B	1.17	3.45 million shs	3.10 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LEGN Legend Biotech	-0.48%	+0.27%	-6.48%	-31.24%	-42.19%
MLTX MoonLake Immunotherapeutics	+2.27%	-5.17%	-21.14%	-46.86%	+18.90%
TLX Telix Pharmaceuticals	+1.82%	+6.26%	-9.16%	+0.63%	+9.47%
TNGX Tango Therapeutics	+5.49%	+2.45%	-0.79%	-23.34%	+244.57%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LEGN Legend Biotech	2.53	Moderate Buy	$55.50	198.07% Upside
MLTX MoonLake Immunotherapeutics	2.43	Hold	$28.50	163.40% Upside
TLX Telix Pharmaceuticals	2.80	Moderate Buy	$20.50	82.87% Upside
TNGX Tango Therapeutics	2.75	Moderate Buy	$43.46	82.53% Upside

Current Analyst Ratings Breakdown

Latest MLTX, LEGN, TNGX, and TLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/9/2026	LEGN Legend Biotech	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$35.00 ➝ $33.00
10/8/2026	LEGN Legend Biotech	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$58.00 ➝ $56.00
10/5/2026	MLTX MoonLake Immunotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$50.00
10/2/2026	LEGN Legend Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/28/2026	LEGN Legend Biotech	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$65.00
9/28/2026	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$65.00
9/25/2026	TLX Telix Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$20.00
9/23/2026	TLX Telix Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$22.00
9/21/2026	TLX Telix Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Moderate Buy
9/16/2026	LEGN Legend Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/16/2026	MLTX MoonLake Immunotherapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LEGN Legend Biotech	$1.03B	3.51	N/A	N/A	$5.43 per share	3.43
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$4.27 per share	N/A
TLX Telix Pharmaceuticals	$803.79M	4.74	$0.04 per share	261.13	$1.23 per share	9.11
TNGX Tango Therapeutics	$53.81M	74.61	N/A	N/A	$2.57 per share	9.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LEGN Legend Biotech	-$296.80M	-$0.25	N/A	15.91	N/A	-7.21%	-8.71%	-5.40%	11/11/2026 (Estimated)
MLTX MoonLake Immunotherapeutics	-$227.32M	-$3.84	N/A	N/A	N/A	N/A	-82.53%	-58.17%	11/4/2026 (Estimated)
TLX Telix Pharmaceuticals	-$7.12M	N/A	N/A	41.52	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	-$101.59M	-$0.85	N/A	N/A	N/A	N/A	-25.75%	-23.36%	11/3/2026 (Estimated)

Latest MLTX, LEGN, TNGX, and TLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	MLTX MoonLake Immunotherapeutics	-$0.77	N/A	N/A	N/A	N/A	N/A
11/3/2026	Q3 2026	TNGX Tango Therapeutics	-$0.34	N/A	N/A	N/A	$3.28 million	N/A
8/11/2026	Q2 2026	LEGN Legend Biotech	$0.07	$0.09	+$0.02	$0.18	$355.96 million	$387.50 million
8/11/2026	Q2 2026	TNGX Tango Therapeutics	-$0.3172	-$0.37	-$0.0528	-$0.37	$1.56 million	N/A
8/10/2026	Q2 2026	MLTX MoonLake Immunotherapeutics	-$0.9086	-$0.84	+$0.0686	-$0.84	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LEGN Legend Biotech	N/A	3.04	2.94
MLTX MoonLake Immunotherapeutics	0.23	12.56	12.56
TLX Telix Pharmaceuticals	1.16	2.01	1.85
TNGX Tango Therapeutics	N/A	50.82	50.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LEGN Legend Biotech	70.89%
MLTX MoonLake Immunotherapeutics	93.85%
TLX Telix Pharmaceuticals	N/A
TNGX Tango Therapeutics	78.99%

Insider Ownership

Company	Insider Ownership
LEGN Legend Biotech	0.02%
MLTX MoonLake Immunotherapeutics	10.40%
TLX Telix Pharmaceuticals	N/A
TNGX Tango Therapeutics	6.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LEGN Legend Biotech	2,965	193.77 million	193.73 million	Optionable
MLTX MoonLake Immunotherapeutics	130	85.11 million	76.26 million	Optionable
TLX Telix Pharmaceuticals	1,184	339.89 million	N/A	N/A
TNGX Tango Therapeutics	137	168.61 million	157.65 million	Optionable

MLTX, LEGN, TNGX, and TLX Headlines

Recent News About These Companies

Comparing Alumis (NASDAQ:ALMS) & Tango Therapeutics (NASDAQ:TNGX)

October 8 at 5:58 AM | americanbankingnews.com

Congress Asset Management Co. Acquires 97,708 Shares of Tango Therapeutics, Inc. $TNGX

October 7 at 3:04 AM | marketbeat.com

Tango Therapeutics Insider Sold Shares Worth $660,796, According to a Recent SEC Filing

October 6, 2026 | marketscreener.comM

Tango Therapeutics (NASDAQ:TNGX) Insider Sells 27,000 Shares of Company Stock

October 6, 2026 | insidertrades.com

Tango Therapeutics (NASDAQ:TNGX) Stock: Insider Adam Crystal Sells 27,000 Shares

October 5, 2026 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Shares Down 5.4% - Here's Why

October 2, 2026 | marketbeat.com

Head-To-Head Analysis: GeoVax Labs (NASDAQ:GOVX) versus Tango Therapeutics (NASDAQ:TNGX)

September 30, 2026 | americanbankingnews.com

Tango Therapeutics, Inc. (TNGX)

September 27, 2026 | finance.yahoo.com

Il principale responsabile contabile di Tango Therapeutics vende azioni per $198k

September 25, 2026 | it.investing.com

Tango Therapeutics (NASDAQ:TNGX) Insider Jessica Newcomb Sells 8,200 Shares of Stock

September 25, 2026 | insidertrades.com

600,834 Shares of Tango Therapeutics, Inc. $TNGX Purchased by Bank of America Corp DE

September 25, 2026 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Stock: Insider Jessica Newcomb Sells 8,200 Shares

September 24, 2026 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Trading 6% Higher - Here's Why

September 22, 2026 | marketbeat.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Rating of "Moderate Buy" from Analysts

September 22, 2026 | marketbeat.com

Squarepoint Ops LLC Sells 155,357 Shares of Tango Therapeutics, Inc. $TNGX

September 19, 2026 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Shares Down 5.6% - Here's What Happened

September 18, 2026 | marketbeat.com

Tidal Investments LLC Purchases Shares of 55,384 Tango Therapeutics, Inc. $TNGX

September 18, 2026 | marketbeat.com

Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?

September 10, 2026 | zacks.com

Tango Therapeutics, Inc. $TNGX Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

September 10, 2026 | marketbeat.com

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 3, 2026 | globenewswire.com

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

September 1, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLTX, LEGN, TNGX, and TLX Company Descriptions

Legend Biotech NASDAQ:LEGN

$18.62 -0.09 (-0.48%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$18.72 +0.10 (+0.52%)

As of 10/9/2026 07:56 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

MoonLake Immunotherapeutics NASDAQ:MLTX

$10.82 +0.24 (+2.27%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$10.93 +0.11 (+1.02%)

As of 10/9/2026 07:30 PM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Telix Pharmaceuticals NASDAQ:TLX

$11.21 +0.20 (+1.82%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$11.22 +0.00 (+0.04%)

As of 10/9/2026 07:30 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Tango Therapeutics NASDAQ:TNGX

$23.81 +1.24 (+5.49%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$23.80 -0.01 (-0.05%)

As of 10/9/2026 07:30 PM Eastern

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MLTX, LEGN, TNGX, and TLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MLTX, LEGN, TNGX, and TLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MLTX, LEGN, TNGX, and TLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLTX, LEGN, TNGX, and TLX Company Descriptions

Legend Biotech NASDAQ:LEGN

MoonLake Immunotherapeutics NASDAQ:MLTX

Telix Pharmaceuticals NASDAQ:TLX

Tango Therapeutics NASDAQ:TNGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MLTX, LEGN, TNGX, and TLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MLTX, LEGN, TNGX, and TLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MLTX, LEGN, TNGX, and TLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLTX, LEGN, TNGX, and TLX Company Descriptions

Legend Biotech NASDAQ:LEGN

MoonLake Immunotherapeutics NASDAQ:MLTX

Telix Pharmaceuticals NASDAQ:TLX

Tango Therapeutics NASDAQ:TNGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools